173 related articles for article (PubMed ID: 15308010)
1. [Establishment of an imatinib resistant cell line K562/G01 and its characterization].
Qi J; Peng H; Gu ZL; Liang ZQ; Yang CZ
Zhonghua Xue Ye Xue Za Zhi; 2004 Jun; 25(6):337-41. PubMed ID: 15308010
[TBL] [Abstract][Full Text] [Related]
2. [Effect of phenylhexyl isothiocyanate on drug-resistance to imatinib in K562/G01 cell line].
Wu RJ; Huang YQ; Ma XD
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):149-52. PubMed ID: 23611223
[TBL] [Abstract][Full Text] [Related]
3. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH
Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
[TBL] [Abstract][Full Text] [Related]
4. [Triptolide inhibits proliferation and induces apoptosis of imatinib resistant K562/G01 cells].
Wen SQ; Ma LM; Lu YJ; Bai B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1148-52. PubMed ID: 24156423
[TBL] [Abstract][Full Text] [Related]
5. [Study on the mechanisms of imatinib-resistance of cancer stem-like cells in K562/Vp16 cell line].
Song YP; Fang BJ; Wei XD; Zheng S
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):669-73. PubMed ID: 16620554
[TBL] [Abstract][Full Text] [Related]
6. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
8. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
[TBL] [Abstract][Full Text] [Related]
9. [Effect of bortezomib on the drug sensitivity of imatinib resistant K562/G01 cells].
Zhou Y; Ma LM; Li XY; Zhang HP; Wang T; Niu YY; Ren RR
Zhonghua Xue Ye Xue Za Zhi; 2011 Jun; 32(6):392-5. PubMed ID: 21781497
[TBL] [Abstract][Full Text] [Related]
10. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
Morinaga K; Yamauchi T; Kimura S; Maekawa T; Ueda T
Int J Cancer; 2008 Jun; 122(11):2621-7. PubMed ID: 18338755
[TBL] [Abstract][Full Text] [Related]
11. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
12. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
14. [CRISPR/Cas9-mediated microRNA-21 knockout increased imatinib sensitivity in chronic myeloid leukemia cells].
Zhang Y; Wang LY; Li JZ; Jiang PF; Hu JD; Chen BY
Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):243-249. PubMed ID: 33910311
[No Abstract] [Full Text] [Related]
15. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.
Peng XX; Tiwari AK; Wu HC; Chen ZS
Chin J Cancer; 2012 Feb; 31(2):110-8. PubMed ID: 22098951
[TBL] [Abstract][Full Text] [Related]
16. An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.
Xing H; Liu T; Meng W; Gong Y
Int J Lab Hematol; 2011 Apr; 33(2):176-81. PubMed ID: 20942869
[TBL] [Abstract][Full Text] [Related]
17. Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.
Karimiani EG; Marriage F; Merritt AJ; Burthem J; Byers RJ; Day PJ
Exp Hematol; 2014 Mar; 42(3):183-191.e5. PubMed ID: 24269846
[TBL] [Abstract][Full Text] [Related]
18. [Effect of tyrosine kinase inhibitor imatinib mesylate on K562 cell invasion by PTEN pathway].
Cheng ZY; Liang WT; Yan XY; Wan JS; Bian YS; Bai P; Liang LQ; Jie JQ; Li AM
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Nov; 28(11):1129-32. PubMed ID: 23127398
[TBL] [Abstract][Full Text] [Related]
19. Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells.
Nambu T; Araki N; Nakagawa A; Kuniyasu A; Kawaguchi T; Hamada A; Saito H
Cancer Sci; 2010 Jan; 101(1):137-42. PubMed ID: 19843070
[TBL] [Abstract][Full Text] [Related]
20. Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
Ju DS; Kim MJ; Bae JH; Song HS; Chung BS; Lee MK; Kang CD; Lee HS; Kim DW; Kim SH
Cancer Lett; 2007 Jul; 252(1):75-85. PubMed ID: 17223257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]